Antagonism Between Wild-type and Mutant β-catenin Controls Hepatoblastoma Differentiation Via Fascin-1
Overview
Authors
Affiliations
Background & Aims: β-catenin is a well-known effector of the Wnt pathway, and a key player in cadherin-mediated cell adhesion. Oncogenic mutations of β-catenin are very frequent in paediatric liver primary tumours. Those mutations are mostly heterozygous, which allows the co-expression of wild-type (WT) and mutated β-catenins in tumour cells. We investigated the interplay between WT and mutated β-catenins in liver tumour cells, and searched for new actors of the β-catenin pathway.
Methods: Using an RNAi strategy in β-catenin-mutated hepatoblastoma (HB) cells, we dissociated the structural and transcriptional activities of β-catenin, which are carried mainly by WT and mutated proteins, respectively. Their impact was characterised using transcriptomic and functional analyses. We studied mice that develop liver tumours upon activation of β-catenin in hepatocytes (APC and β-catenin mice). We used transcriptomic data from mouse and human HB specimens, and used immunohistochemistry to analyse samples.
Results: We highlighted an antagonistic role of WT and mutated β-catenins with regard to hepatocyte differentiation, as attested by alterations in the expression of hepatocyte markers and the formation of bile canaliculi. We characterised fascin-1 as a transcriptional target of mutated β-catenin involved in tumour cell differentiation. Using mouse models, we found that fascin-1 is highly expressed in undifferentiated tumours. Finally, we found that fascin-1 is a specific marker of primitive cells including embryonal and blastemal cells in human HBs.
Conclusions: Fascin-1 expression is linked to a loss of differentiation and polarity of hepatocytes. We present fascin-1 as a previously unrecognised factor in the modulation of hepatocyte differentiation associated with β-catenin pathway alteration in the liver, and as a new potential target in HB.
Impact And Implications: The gene, encoding fascin-1, was reported to be a metastasis-related gene in various cancers. Herein, we uncover its expression in poor-prognosis hepatoblastomas, a paediatric liver cancer. We show that fascin-1 expression is driven by the mutated beta-catenin in liver tumour cells. We provide new insights on the impact of fascin-1 expression on tumour cell differentiation. We highlight fascin-1 as a marker of immature cells in mouse and human hepatoblastomas.
Specific features of ß-catenin-mutated hepatocellular carcinomas.
Dantzer C, Dif L, Vache J, Basbous S, Billottet C, Moreau V Br J Cancer. 2024; 131(12):1871-1880.
PMID: 39261716 PMC: 11628615. DOI: 10.1038/s41416-024-02849-7.
Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine.
Bakrania A, To J, Zheng G, Bhat M Gastro Hep Adv. 2024; 2(7):948-963.
PMID: 39130774 PMC: 11307499. DOI: 10.1016/j.gastha.2023.07.012.
Dantzer C, Vache J, Brunel A, Mahouche I, Raymond A, Dupuy J Elife. 2024; 13.
PMID: 39008536 PMC: 11249736. DOI: 10.7554/eLife.95191.
A rare case report: multiple intrahepatic masses in a pediatric patient with citrin deficiency.
Lin H, Jiang H, Chen Q, Pan X, Deng M, Cai X Discov Oncol. 2024; 15(1):200.
PMID: 38819760 PMC: 11143117. DOI: 10.1007/s12672-024-01059-0.